CORDIS
EU research results

CORDIS

English EN

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Project information

Grant agreement ID: 853932

Status

Ongoing project

  • Start date

    1 May 2019

  • End date

    30 April 2025

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 8 060 640,75

  • EU contribution

    € 5 687 983,75

Coordinated by:

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

Objective

Non-tuberculous mycobacteria, such as Mycobacterium avium complex (MAC) and Mycobacterium abscessus, cause lung diseases resembling TB, mainly in immune-compromised patients or patients suffering from other lung diseases (e.g. cystic fibrosis). The incidence and prevalence of lung diseases caused by NTM are increasing worldwide. Importantly, in the US and Japan, as well as in other areas of the world where TB has declined, NTM disease is already at least three times more prevalent than TB. Treatment of NTM diseases relies on antibiotic combinations, however the drugs active against NTM are rather few and mainly different than those active against TB. These NTM treatments for the most common species (MAC and M. abscessus) are much less active than the current anti-TB regimen is for TB treatment. It is often necessary to administer antibiotic combinations for at least 12-24 months. The long and complex drug regimen that is currently recommended as a treatment against NTM-caused diseases carries the risk of inducing resistance in NTM. Several studies have already shown the existence and emergence of multidrug resistant NTM. The overall objective of RESPIRI-NTM is to find new drug candidates as potential components of a new, more efficient combination drug regimen against NTM that is less prone to resistance and allows shortening of treatment duration for NTM and multidrug-resistant NTM. Such a drug combination will synergistically target the energy metabolism of NTM or complementary targets. To achieve this, we will advance recently discovered inhibitors of the mycobacterial respiratory pathway. In addition, we will perform a novel, phenotypic screen in order to identify novel targets in NTM. Finally, we will also target host-factors that are essential for the intracellular survival of NTM. Together, we present a comprehensive plan to find novel strategies to combat non-tuberculous mycobacteria, shorten treatment time and reduce chances of drug resistance.

Coordinator

ACADEMISCH ZIEKENHUIS LEIDEN

Address

Albinusdreef 2
2333 Za Leiden

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 570 226,25

Participants (8)

UNIVERSITEIT LEIDEN

Netherlands

EU Contribution

€ 766 250

UNIVERSITEIT ANTWERPEN

Belgium

EU Contribution

€ 1 191 325

SORBONNE UNIVERSITE

France

EU Contribution

€ 726 750

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 848 750

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 260 067,50

JANSSEN PHARMACEUTICA NV

Belgium

MITOLOGICS

France

EU Contribution

€ 153 060

FFUND BV

Netherlands

EU Contribution

€ 171 555

Project information

Grant agreement ID: 853932

Status

Ongoing project

  • Start date

    1 May 2019

  • End date

    30 April 2025

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 8 060 640,75

  • EU contribution

    € 5 687 983,75

Coordinated by:

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands